Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder
NCT07355842, Not applicable, Recruiting, University of Zurich
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Role of Slow Waves in the Progression of Neurodegeneration in Isolated REM Sleep Behavior Disorder | ClinicalTrials.gov |
| NCT number | NCT07355842 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Zurich | ClinicalTrials.gov |
| Conditions | Parkinson Disease, REM Sleep Behavior Disorder (iRBD) | ClinicalTrials.gov |
| Interventions | Tosoo Axora, Tosoo Axora | ClinicalTrials.gov |
| First posted | 2026-01-21 | ClinicalTrials.gov |
| Last updated | 2026-02-17 | ClinicalTrials.gov |
Registered outcomes 43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Presynaptic Dopaminergic Integrity | assessed at Baseline Visit and Closeout Visit (after 18 months) | Striatal dopaminergic function as measured by high-resolution 18F-Fluorodopa (18F-DOPA)-PET imaging. | ClinicalTrials.gov |
| Secondary | MDS-UPDRS Part III Score | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Motor symptom severity assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III), a clinician-rated examination of motor signs. | ClinicalTrials.gov |
| Secondary | Purdue Pegboard Test Score | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Manual dexterity and fine motor coordination assessed by total score on the Purdue Pegboard Test. | ClinicalTrials.gov |
| Secondary | Alternate Finger Tapping Test | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Motor speed and coordination assessed by performance on the Alternate Finger Tapping Test. | ClinicalTrials.gov |
| Secondary | UPDRS I.1 (subjective cognition) | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Patient-reported cognitive experiences of daily living assessed by MDS-UPDRS Part I, Item 1.1. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment (MoCA) Score | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout) | Global cognitive function assessed by MoCA total score. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part A | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Processing speed and attention assessed by time to completion on Trail Making Test Part A. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part B | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Executive function assessed by time to completion on Trail Making Test Part B. | ClinicalTrials.gov |
| Secondary | Digit Span Forward | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Attention assessed by Digit Span Forward from the Wechsler Adult Intelligence Scale. | ClinicalTrials.gov |
| Secondary | Digit Span backward | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Working memory assessed by Digit Span Backward from the Wechsler Adult Intelligence Scale | ClinicalTrials.gov |
| Secondary | Stroop Test | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Executive function and inhibitory control assessed by Stroop Color-Word Test. | ClinicalTrials.gov |
| Secondary | Verbal Fluency - Semantic | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Semantic verbal fluency assessed by category fluency task. | ClinicalTrials.gov |
| Secondary | Benton Judgment of Line Orientation (BJLO) | assessed at each visit (Baseline, after 6 months, after 12 months, after 18 months (Closeout)) | Visuospatial function assessed by Benton Judgment of Line Orientation test. | ClinicalTrials.gov |
| Secondary | LPS-4 Logical Reasoning | assessed at Baseline Visit and Closeout Visit (after 18 months) | Logical reasoning assessed by Leistungsprüfsystem subtest 4. | ClinicalTrials.gov |
| Secondary | Rey-Taylor Complex Figure Test - Copy | assessed at Baseline Visit and Closeout Visit (after 18 months) | Visuoconstruction assessed by copy trial of the Rey-Taylor Complex Figure Test. | ClinicalTrials.gov |
| Secondary | Rey-Taylor Complex Figure Test - Recall | assessed at Baseline Visit and Closeout Visit (after 18 months) | Visual memory assessed by delayed recall of the Rey-Taylor Complex Figure Test. | ClinicalTrials.gov |
| Secondary | California Verbal Learning Test (CVLT) | assessed at Baseline Visit and Closeout Visit (after 18 months) | Verbal learning and memory assessed by California Verbal Learning Test. | ClinicalTrials.gov |
| Secondary | Verbal Fluency - Phonemic | assessed at Baseline Visit and Closeout Visit (after 18 months) | Phonemic verbal fluency assessed by letter fluency task. | ClinicalTrials.gov |
| Secondary | Boston Naming Test (BNT) | assessed at Baseline Visit and Closeout Visit (after 18 months) | Naming and language function assessed by Boston Naming Test | ClinicalTrials.gov |
| Secondary | WAIS Similarities | assessed at Baseline Visit and Closeout Visit (after 18 months) | Verbal abstract reasoning assessed by similarities subtest from the Wechsler Adult Intelligence Scale | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 13
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Finger Tapping Task | Secondary outcome | ConductCognition |
| Line Angle Matching | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Psychomotor Vigilance Task | Other outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Sustained Attention to Response | Other outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)